365英国上市公司

Be the most trusted biotech company

2019-12-09

First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 DLBCL Study
2019-12-05

Henlius and FARMA DE COLOMBIA Enter into Exclusive License Agreement for Rituximab HLX01
2019-11-27

A Novel Anti-PD-1 Antibody HLX10 Study Led to the Initiation of Combination Immunotherapy
2019-11-27

A Novel Anti-EGFR Antibody HLX07 for Potential Treatment of Squamous Cell Carcinoma of the Head and Neck
2019-11-26

First China-Manufactured Trastuzumab Biosimilar HLX02 Global Phase 3 Trial Met Primary Endpoint in Breast Cancer
2019-11-06

Henlius 汉利康®（Rituximab Injection）Wins“Biosimilar Initiative of the Year” at Global Generics & Biosimilars Awards 2019
2019-10-31

Henlius Anti-HER2 Monoclonal Antibody HLX11 Received IND Application Acceptance Notification from NMPA
2019-10-17

Henlius Innovative Anti-cMET Monoclonal Antibody HLX55 Received Clinical Approval from NMPA
2019-10-12

The breakthrough of China-manufactured trastuzumab biosimilar (HLX02) for metastatic breast cancer︱Interview of Prof. Binghe Xu and Prof. Igor Bondarenko at ESMO Congress 2019